CAJ | 학술논문

目的观察康莱特注射液辅助治疗中晚期非小细胞肺癌的临床效果.方法将61例晚期非小细胞肺癌患者随机分为治疗组31例和对照组30例,两组均给予综合治疗,治疗组在此基础上加用康莱特注射液200 ml静脉滴注,观察两组生活质量疗效、疼痛缓解情况、临床疗效和不良反应等情况.结果 (1)生活质量疗效:治疗组改善20例(64.5％),稳定8例(25.8％),下降3例(9.7％)；对照组分别为9例(30.0％),9例(30.0％),12例(40.0％),治疗组优于对照组(U=2.91,P＜0.01).(2)疼痛缓解情况:治疗组完全缓解、部分缓解、无变化、进展者分别为5例(16.1％),16例(51.6％),6例(19.4％),4例( 12.9％)；对照组分别为2例(6.7％),9例(30.0％),11例(36.7％),8例(26.7％),治疗组优于对照组(U=2.32,P＜0.05).(3)临床疗效:治疗组部分缓解、稳定、进展者分别为12例(38.7％),14例(45.2％),5例(16.1％),对照组分别为8例(26.7％),8例(26.7％),14例(46.7％),治疗组优于对照组(U=2.04,P＜0.05).(4)不良反应:治疗组白细胞计数和胃肠道反应Ⅲ、Ⅳ度发生率分别为22.6％ (7/31)和19.4％ (6/31),而对照组分别为53.3％ (16/30)和46.7％ (14/30),差异均有统计学意义(x2值分别为6.139和5.161,P均＜0.05).结论康莱特注射液联合治疗可提高晚期非小细胞肺癌临床疗效,减轻不良反应,保护免疫功能,提高患者生存质量.
목적 관찰강래특주사액보조치료중만기비소세포폐암적림상효과.방법 장61례만기비소세포폐암환자수궤분위치료조31례화대조조30례,량조균급여종합치료,치료조재차기출상가용강래특주사액200 ml정맥적주,관찰량조생활질량료효、동통완해정황、림상료효화불량반응등정황.결과 (1)생활질량료효:치료조개선20례(64.5％),은정8례(25.8％),하강3례(9.7％)；대조조분별위9례(30.0％),9례(30.0％),12례(40.0％),치료조우우대조조(U=2.91,P＜0.01).(2)동통완해정황:치료조완전완해、부분완해、무변화、진전자분별위5례(16.1％),16례(51.6％),6례(19.4％),4례( 12.9％)；대조조분별위2례(6.7％),9례(30.0％),11례(36.7％),8례(26.7％),치료조우우대조조(U=2.32,P＜0.05).(3)림상료효:치료조부분완해、은정、진전자분별위12례(38.7％),14례(45.2％),5례(16.1％),대조조분별위8례(26.7％),8례(26.7％),14례(46.7％),치료조우우대조조(U=2.04,P＜0.05).(4)불량반응:치료조백세포계수화위장도반응Ⅲ、Ⅳ도발생솔분별위22.6％ (7/31)화19.4％ (6/31),이대조조분별위53.3％ (16/30)화46.7％ (14/30),차이균유통계학의의(x2치분별위6.139화5.161,P균＜0.05).결론 강래특주사액연합치료가제고만기비소세포폐암림상료효,감경불량반응,보호면역공능,제고환자생존질량.
Objective To study the effect of Kanglaite combined with comprehensive therapy on advanced non-small cell lung cancer.Methods Sixty-one patients with advanced non-small cell lung cancer were randomly divided into treatment group ( n=31 ) and control group ( n=30 ).Both groups were given comprehensive therapy.Treatment group were additionally treated with intravenous injection of 200 ml Kanglaite.Clinical efficacy,quality of life,pain relief and adverse reactions of the two groups were observed.Results ( 1 ) Quality of life was improved in 20 cases (64.5％ ),stabled in 8 cases (25.8％),declined in 3 cases ( 9.7％ ) of treatment group,and in the control group there were 9 cases ( 30.0％ ) improved,9 cases ( 30.0％ ) stabilized,12 cases (40.0％ ) declined respectively.Quality of life in treatment group was higher than in control group ( U=2.91,P＜0.01 ).( 2 ) Pain relief:the number of patients with complete remission,partial remission,no change,and progression were 5 cases ( 16.1％ ),16 cases ( 51.6 ％ ),16 cases (51.6％ ),6 cases (19.4％) and 4 cases (12.9％ ) in treatment group,and in control group they were 2 cases(6.7％ ),9 cases (30.0％ ),11 cases(36.7％ ) and 8 cases(26.7％ ) respectively.The effect of treatment on pain relief in treatment group was better than that in control group ( U=2.32,P＜0.05 ).(3) Clinical efficacy:in the treatment group there were 12 cases (38.7％) with partial remission,14 cases (45.2％) stabilized,and 5 cases (16.1％ ) progressed,and in control group the numbers were 8 cases (26.7％ ),8 cases (26.7％ ) and 14 cases (46.7％ ) respectively.The clinical efficacy in treatment group was better than that in the control group( U=2.04,P＜0.05).(4) There were significant difference on the change of white blood cell count and gastrointestinal reactions Ⅲ and Ⅳ degrees between treatment group and contrl group [22.6％ (7/31) vs.53.3％(16/30),x2=6.139 P＜0.05;19.4％ (6/31) vs.46.7％ (14/30),x2=5.161,P＜0.05].Conclusion Kanglaite injection combined with comprehensive therapy can improve clinical efficacy of therapy for advanced non-small cell lung cancer,reduce the toxic adverse reaction,protect immunity system and improve the quality of life of patients.